Recent Updates
Recently added Catalysts
SKYE Neutral Sentiment

Using Arecor’s Arestat Technology to Increase Drug Dosing

Key Takeaway: Skye Bioscience has announced the use of Arecor's Arestat technology to enhance drug dosing. This development was published on January 4, 2026. The article does not provide further details on the implications or applications of this technology in drug development.
Price reaction · baseline $0.8782 (2026-01-02 close) · 3 other SKYE headline(s) in the window, move may be shared
day 0 close
-2.3%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+84%
120-day peak, hindsight
Typical move
24.3%
average across 4 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
Nimacimab
Phase 2 · Obesity

Full Press Release Details

Bioscience Bioscience Obesity Nasdaq: SKYE © 2026 Skye Bioscience. All Rights Reserved. All Primers Perspectives Progress Press Using Arecor’s Arestat Technology to Increase Drug Dosing Date published: January 4, 2026 9:05 pm PST Share
Last updated: Jan 4, 2026